Accéder au contenu
Merck
Toutes les photos(4)

Key Documents

05-1410-M

Sigma-Aldrich

Anti-CD45 Antibody, clone F10-89-4

clone F10-89-4, from mouse, purified by affinity chromatography

Synonyme(s) :

CD45 antigen, Leukocyte common antigen precursor, SCID due to PTPRC deficiency, T200 glycoprotein, T200 leukocyte common antigen, Human homolog of severe combined immunodeficiency due to PTPRC deficiency, Leukocyte-common antigen, Protein tyrosine phosph

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme


About This Item

Code UNSPSC :
12352203
eCl@ss :
32160702
Nomenclature NACRES :
NA.41

Source biologique

mouse

Niveau de qualité

Forme d'anticorps

affinity isolated antibody

Type de produit anticorps

primary antibodies

Clone

F10-89-4, monoclonal

Produit purifié par

affinity chromatography

Espèces réactives

mouse

Réactivité de l'espèce (prédite par homologie)

human, rat

Technique(s)

flow cytometry: suitable
immunofluorescence: suitable
immunohistochemistry: suitable (paraffin)
immunoprecipitation (IP): suitable
western blot: suitable

Isotype

IgG2a

Numéro d'accès NCBI

Numéro d'accès UniProt

Modification post-traductionnelle de la cible

unmodified

Informations sur le gène

human ... PTPRC(5788)

Description générale

CD45 is a receptor-tyrosine phosphatase required for antigen-induced signaling in T-cells and B-cells; its substrates are unknown. Interestingly, it associates with several Src-family tyrosine kinases, which are inhibited by tyrosine phosphorylation in their c-termini, suggesting a mechanism for signaling by CD45.

Spécificité

This antibody reacts with the leucocyte common antigen (LCA) complex to be found on lymphocytes, monocytes, granulocytes, thymocytes and malignant T and B cells. No reactivity has been observed with primary or metastatic carcinoma cells. Plasma cells or myeloma cells may have weak expression or be negative for this antigen.
The LCA comprises of at least 5 isoforms ranging from 180-220 kDa which are produced as a result of alternative splicing of exons A, B or C. CBL 124 recognizes epitopes common to
all of the isoforms.
Antigen distribution:
Thymocytes >95%
Granulocytes >95%
Monocytes >95%
B cells (CD20+) >95%
T cells (CD3+) >95%
NK cells (CD16+) >95%
Peripheral blood lymphocytes >95%
FUSION PARTNER: NS1 myeloma cell line

Immunogène

Purified T cells from human lymph nodes

Application

Anti-CD45 Antibody, clone F10-89-4 detects level of CD45 & has been published & validated for use in FC, WB, IF, IP, IH(P).
Immunofluorescence: A previous lot of this antibody was used in the identification of cells of leucocyte origin by indirect staining.

Immunohistochemistry (paraffin): A previous lot of this antibody was used in the discrimination between malignant cells of haematopoietic origin and other malignancies in frozen tissue sections.

Immunoprecipitation: A previous lot of this antibody was used in studies of the leucocyte common antigen complex and its identification by the Western blotting technique.

Flow Cytometry: Studies of CD45 expression and the association with T-cell receptor signaling was performed using this antibody of previous lot.
Studies of the mechanism by which CD45 regulates B cell activation through protein tyrosine phospatases.
Optimal working dilutions must be determined by the end user.

Immunohistochemistry(paraffin): Representative testing from a previous lot.

Optimal Staining of CD45 Monoclonal Antibody: Tonsil
Research Category
Signaling
Research Sub Category
Immunological Signaling

Qualité

Routinely evaluated by Western Blot on jurkat cell lysate.

Western Blot Analysis: 1:500 dilution of this lot detected CD45 on 10 μg of Jurkat lysates

Description de la cible

~180-220 kDa

Liaison

Replaces: 04-1102

Forme physique

Protein A affinity chromatography
Purified mouse monoclonal IgG2a presented in phosphate buffered saline containing 10 mM sodium azide and 1 mg/mL bovine serum albumin.
We recommend that each laboratory determine an optimum working titre for use in its particular application.

Stockage et stabilité

For use within 1 month of purchase store at 2-8°C, for long term storage aliquot antibody into small volumes and store at -20°C for up to one year from date of receipt.
Handling Recommendations: Upon first thaw, and prior to removing the cap, centrifuge the vial and gently mix the solution. Aliquot into microcentrifuge tubes and store at -20°C. Avoid repeated freeze/thaw cycles, which may damage IgG and affect product performance.

Remarque sur l'analyse

Control
Jurkat cell lysate

Autres remarques

Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.

Clause de non-responsabilité

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Vous ne trouvez pas le bon produit ?  

Essayez notre Outil de sélection de produits.

Code de la classe de stockage

12 - Non Combustible Liquids

Classe de danger pour l'eau (WGK)

WGK 2

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable


Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Increased Infiltration of Extra-Cardiac Cells in Myxomatous Valve Disease.
Sauls, K; Toomer, K; Williams, K; Johnson, AJ; Markwald, RR; Hajdu, Z; Norris, RA
Journal of cardiovascular development and disease null
The effect of stromal cell-derived factor-1?/heparin coating of biodegradable vascular grafts on the recruitment of both endothelial and smooth muscle progenitor cells for accelerated regeneration.
Jian Yu,Aijun Wang,Zhenyu Tang,Jeffrey Henry,Benjamin Li-Ping Lee,Yiqian Zhu,Failei Yuan et al.
Biomaterials null
Olena Preobrazhenska et al.
PloS one, 7(6), e39761-e39761 (2012-07-05)
Chronic obstructive lung disease (COPD) is characterized by matrix deposition in the small airways but matrix loss from the parenchyma, phenomena which must depend on the ability of local fibroblasts to produce matrix after smoke exposure. To investigate this idea

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique